A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national phase III clinical trial
New overall survival data of two phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, demonstrated that patients with advanced non-small cell lung cancer whose tumors have the most common epidermal growth factor receptor mutation lived longer if treated with first-line afatinib compared to chemotherapy.
From left to right: Eddie Reed, then-NCI Director Sam Broder, and Brawley in 1991. Reed was receiving an award for his role in developing Taxol.Reed, 60, had liver cancer. Many of us will remember Eddie for his achievements. They were many and spectacular. In the late 1980s, I was the other and younger Black doctor in the Medicine Branch at NCI. I will remember him as a cancer doc, an intense man with high standards.
FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase III trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, was successful in achieving statistical significance for its primary and all secondary endpoints.
In a phase I study, tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
Merck announced new biomarker findings from a retrospective analysis of the completed phase III study that compared Erbitux (cetuximab) plus FOLFIRI with FOLFIRI alone.
A study found that it may be safe to postpone androgen deprivation therapy in men with a PSA-only based relapse after prostate surgery or radiation therapy.
The American Society of Clinical Oncology published two clinical practice guidelines on treating women with advanced, HER2-positive breast cancer.
